All In MedTech

Device Trial Radar · NCT03241459

Safety and Efficacy of the SurVeil™ Drug-Coated Balloon

Randomized & Controlled Noninferiority Trial to Evaluate Safety & Clinical Efficacy of SurVeil™ Drug-Coated Balloon (DCB) iN Treatment of Subjects With Stenotic Lesions of Femoropopliteal Artery Compared to Medtronic IN.PACT® Admiral® DCB

Last checked: Nov 19, 2026Latest source record: Mar 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 446 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

446

Actual

Start

Oct 23, 2017

Primary completion

Sep 15, 2020

Study completion Sep 17, 2024

Sponsor

Lead sponsor
SurModics, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Aug 7, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To demonstrate the safety and efficacy of the SurVeil Drug-Coated Balloon (DCB) for treatment of subjects with symptomatic peripheral artery disease (PAD) due to stenosis of the femoral and/or popliteal arteries.

Conditions

  • Peripheral Arterial Disease
  • Peripheral Vascular Disease
  • Artery Disease, Peripheral
  • Femoropopliteal Artery Occlusion

Interventions

  • Surmodics SurVeil DCBDevice

    Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.

  • Medtronic IN.PACT Admiral DCBDevice

    Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Lesion Patency Though 12 MonthsTime frame: 12 months
  2. Safety Composite of Freedom From Death, Amputation, and Target Vessel Revascularization (TVR)Time frame: 12 months

Locations

63 sites in 9 countries. Site status is shown where the registry gives one.

  • Cardiovascular Associates of the Southeast

    Birmingham, Alabama

  • Cardiology Associates

    Foley, Alabama

  • Dignity Health

    Gilbert, Arizona

60 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.